The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.

Compositions are disclosed herein comprising at least one dextran ether compound that comprises uncharged, anionic, and/or cationic organic groups. The degree of substitution of one or more dextran ether compounds is about 0.0025 to about 3.0. Dextran from which the disclosed ether compounds can be derived can have a weight-average molecular weight of about 50-200 million Daltons and/or a z-average radius of gyration of about 200-280 nm. Also disclosed are methods of producing dextran ether compounds, as well as methods of using these ether compounds in various applications.

A nucleophilic substitution reaction to crosslink cyclodextrin (CD) polymer with rigid aromatic groups, providing a high surface area, mesoporous CD-containing polymers (P-CDPs). The P-CDPs can be used for removing organic contaminants from water. By encapsulating pollutants to form well-defined host-guest complexes with complementary selectivities to activated carbon (AC) sorbents. The P-CDPs can rapidly sequester pharmaceuticals, pesticides, and other organic micropollutants, achieving equilibrium binding capacity in seconds with adsorption rate constants 15-200 times greater than ACs and nonporous CD sorbents. The CD polymer can be regenerated several times, through a room temperature washing procedure, with no loss in performance.

The invention relates to a complex of pure anthocyanidin and a sulfoalkyl ether -cyclodextrin, which complex can be formulated as an aqueous solution and as a solid, and a method for producing such a complex. Complexes according to the invention are storage-stable and can be well formulated as an aqueous solution.

A medical device for the treatment of papilloma virus (HPV) skin infections is the object of this invention, in particular for the treatment of warts and related pathologies. In particular, this invention relates to acetylsalicylic acid for use in the topical treatment, of HPV skin infections in particular benign infections and more in particular warts. Acetylsalicylic acid may be administered by plaster or patch, both in a solid state, such as a tablet, powder or granulate, and by a hydrophilic or hydrophobic gel.

The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.

The present invention relates to a biocompatible nanoparticle and a use thereof and, more specifically, to a biocompatible nanoparticle formed by irradiation an electron beam to an aqueous solution comprising at least one substance selected from the group consisting of a polysaccharide, a derivative thereof and a polyethylene glycol, thereby inducing inter-molecular cross-linking or intra-molecular cross-linking, and to a use of the biocompatible nanoparticle in a drug carrier, a contrast agent, a diagnostic agent or an intestinal adhesion prevention agent or for disease prevention and treatment.

The invention deals with a novel process for making intermediates of the pharmaceutically useful product Sugammadex of formula (1). ##STR00001##

A method for refining sugammadex sodium is provided: adding a protective agent to crude sugammadex sodium, and obtaining pure sugammadex sodium by performing recrystallization under the protection of inert gas. Among them, the protective agent is one or a mixture of two or more, in any ratio, selected from the group consisting of mercaptoethanol, thioglycolate, thioglycolate ester, mercaptopropionate, mercaptopropionate ester, glutathione, cysteine, cystamine, dithioerythritol, dithiothreitol, trisubstituted organophosphorus compound, and salt of the trisubstituted organophosphorus compound. The method is simple in operation, high in product purity, good in economy, and more suitable for industrial production.

Provided are supramolecular polypseudorotaxane hydrogel compositions and 3-D structures capable of reversible 3-D structural deformation which include (a) a solvent; (b) an at least partially linear polymer, where the polymer further comprises groups capable of covalent crosslinking between the polymers; (ii) at least one first macrocyclic ring which forms a pseudorotaxane with a polymer in the polymer network; and (iii) at least one second macrocyclic ring that does not form the pseudorotaxane. The hydrogel composition has a viscosity which allows for 3-D printing of the hydrogel to form a 3-D structure, and a storage (elastic) modulus after crosslinking that allows for the 3-D structure to undergo reversible 3-D structural deformation upon change of solvent conditions. Also provided are methods of manufacturing the compositions and 3-D structures.